PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs CRVO's -7.49%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Cash + STI yoy 0.5-0.75x CRVO's -7.49%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-4.22%
0.5-0.75x CRVO's -7.10%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-17.65%
Below half CRVO's -100.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x CRVO's -0.01%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-47.54%
0.5-0.75x CRVO's -90.58%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
0.5-0.75x CRVO's -7.44%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
46.70%
1.1-1.25x CRVO's 39.74%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
-26.38%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
265.71%
Less than half of CRVO's -10.48%. David Dodd sees fewer expansions in other current obligations.
63.25%
Above 1.5x CRVO's 6.50%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x CRVO's 6.50%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
1.25-1.5x CRVO's -2.75%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
Similar yoy to CRVO's -8.44%. Walter Schloss sees parallel net worth trends.
-4.84%
0.5-0.75x CRVO's -7.44%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Both CRVO and the company show zero Total Investments Growth.
-26.37%
Less than half of CRVO's -100.00%. David Dodd sees less overall debt expansion vs. competitor.
5.01%
50-75% of CRVO's 7.34%. Bruce Berkowitz notes comparatively lower net debt expansion.